Newer Drugs Not Cost-Effective for First-Line Diabetes Therapy

Costs of SGLT2 inhibitors and GLP-1 receptor agonists 'need to be lowered substantially' to improve health outcomes and prevent health disparities in patients with type 2 diabetes, say researchers.

Related Keywords

Illinois ,United States ,University Of Chicago ,United Kingdom ,Jing Choi ,Neda Laiteerapong ,Nutrition Examination Survey ,National Health ,Drug Administration ,Chronic Disease Research ,Medscape Medical News ,Affordable Insulin Now Act ,Prices Too High ,Encourage First Line ,United Kingdom Prospective Diabetes Study ,Outcomes Model ,Could Remain ,Diabetes Mellitus Type 2 ,Iabetes Mellitus Type Ii ,Type 2 Diabetes ,Diabetes ,Diabetes Mellitus ,Sglt2 Inhibitors ,Odium Glucose Transporter 2 Inhibitors ,Odium Glucose Co Transporter 2 Inhibitors ,Sodium Glucose Cotransporter 2 Inhibitors ,Endocrinology ,Ndocrine System ,Hemoglobin A1c ,Hemoglobin A1c Test ,Glycated Hemoglobin ,Glycosylated Hemoglobin ,Ba1c ,A1c ,B1c ,Lycohemoglobin ,Hb ,Viab ,